TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

Cécile L Tremblay; Françoise Giguel; Yongbiao Guan; Ting-Chao Chou; Katsunori Takashima; Martin S Hirsch

doi:10.1128/AAC.49.8.3483-3485.2005

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5. doi: 10.1128/AAC.49.8.3483-3485.2005.

Authors

Cécile L Tremblay¹, Françoise Giguel, Yongbiao Guan, Ting-Chao Chou, Katsunori Takashima, Martin S Hirsch

Affiliation

¹ Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139, USA. mshirsch@partners.org

Abstract

TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

MeSH terms

Anti-HIV Agents / pharmacology*
CCR5 Receptor Antagonists*
Drug Synergism
HIV Infections / virology
HIV-1 / drug effects*
Humans
Leukocytes, Mononuclear / virology
Reverse Transcriptase Inhibitors / pharmacology*

Substances

Anti-HIV Agents
CCR5 Receptor Antagonists
Reverse Transcriptase Inhibitors